Medtronic’s financial results for its first quarter of fiscal year 2011, which ended July 30, revealed a double-digit increase in net earnings, despite a slight drop in revenues.
Medical technology companies Medtronic and Osteotech have entered into a definitive agreement for Medtronic to acquire Osteotech for $6.50 per share in cash for each share of Osteotech common stock. The total value of the transaction is expected to be approximately $123 million.
Handheld device sales for healthcare use reached $8.2 billion globally in 2009 and are expected to increase 7 percent for the next five years as physicians and hospitals purchase new IT systems, according to a report from healthcare market research publisher Kalorama Information.
Medtronic has reported impressive financial results for its 2010 fourth quarter and fiscal year, which ended April 30.
The FDA has granted 510(k) clearance for Medtronic’s PoleStar N30 Surgical MRI system for neuro-oncology surgical procedures. The company simultaneously launched the imaging system.
By not wearing appropriate radiation protection, spine surgeons performing high volumes of cases could approach the annual cumulative exposure limit of 5 Rem to the thyroid or torso, according to research to be presented during the America Association of Neurological Surgeons (AANS) annual conference, May 1-5 in Philadelphia.
The FDA’s Circulatory System Devices Panel of the Medical Devices Advisory Committee has voted unanimously in favor of approving with conditions Medtronic’s Revo MRI SureScan pacing system designed as MR conditional, or safe for use in MRI systems under specified conditions.
Written by Kaitlyn Dmyterko
ATLANTA—For patients with implanted cardiac devices, MRI has never been a viable way to obtain diagnostic tests due to device contraindications and risks. However, new research has found that MRI testing in this patient population can be performed at little or no risk, Robert H. Helm, MD, from Boston Medical Center, said during a presentation at the American College of Cardiology (ACC) scientific sessions on Monday.
Medtronic is partnering with Vital Images to provide imaging and advanced visualization services for endovascular specialists who use Medtronic's portfolio of stent grafts to treat aortic aneurysms.
Abbott today settled all outstanding intellectual property litigation with Medtronic. Under the terms of the settlement, Medtronic will pay Abbott $400 million and $42 million to evYsio Medical Devices, based in Vancouver, British Columbia.
Medtronic has received the European CE Mark for its second-generation pacemaker for use with MRI machines, the Advisa DR MRI SureScan pacing system.
Medtronic plans to reduce its global work force by 1,500 to 1,800 employees, in an effort to further align the company with its long-term growth outlook.
BOSTON--In the MRI environment under specific guidelines, a new pacemaker system facilitates access to this diagnostic imaging technique with no evidence of clinical (bradycardia or tachycardia), subclinical (pacemaker performance) or technical (pacemaker or lead damage) deficits in patients, according to a late-breaking clinical pivotal trial presented May 14 at the 2009 meeting of the Heart Rhythm Society (HRS).
Medtronic has requested that the Centers for Medicare & Medicaid Services (CMS) revise national coverage determination for cardiac pacemakers to include coverage for devices that have been designed, tested and FDA labeled for use in the MRI environment.
In a surprise decision, the Supreme Court ruled 6-3 today that Vermont resident, Diana Levine, can sue Wyeth for injuries she suffered after she was administered one of the company's FDA-approved drugs.
Tuesday, February 24 2009
Medtronic today acquired Ventor Technologies, a developer of transcatheter heart valve technologies for the treatment of aortic valve disease, for a payment of $325 million. The company also signed a definitive agreement today to acquire CoreValve for $700 million, plus additional payments contingent upon the achievement of agreed milestones.
Medtronic reported strong growth in profits for the medical device manufacturer's fiscal 2009 third quarter, which ended Jan. 23.
Boston Scientific and Medtronic have settled two lawsuits and signed an agreement to stand down in three others, which will stop all current litigation between the two companies in the fields of interventional cardiology and endovascular repair.
The prevailing notion is that bypass surgery is superior to stenting in patients with diabetes. The truth, however, is more complicated, as the decision-makers learn to examine the individual pathologies in lieu of standardization. Often, this process is more art than science in taking into account all of the parameters of a patient’s disease.
The use of advanced visualization software enables the utilization of coronary CT angiography (CCTA) to accurately depict stent fractures in patients that are not clearly depicted by conventional angiography, according to a study published in the December issue of Radiology.
|